Intratumoral immune activation with TLR4 agonist synergizes with effector T cells to eradicate established murine tumors.

NPJ Vaccines · 2020 · PMC7298055 · PMID 32579133

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

1b ), leading to highly significant long-term survival with no tumor recurrence over at least 120 days (Fig. 1c ).

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.